Purpose: This work evaluates the use of target and organs at risk (OAR) dose-volume goals in 3D conformal radiotherapy (3DCRT) planning for node positive breast cancer (NPBC) patients undergoing regional nodal irradiation after lumpectomy/mastectomy. Methods: Dosimetric data for 262 NPBC patients receiving regional nodal and whole breast/chest wall (WB/CW) irradiation from 2000-2009 were analyzed. In all cases, target & OAR volumes were delineated on treatment CT scans for field generation and dose-volume histograms (DVHs) were generated. Cases were analyzed to identify how frequently they met treatment planning institutional dose-volume goals ("institutional guidelines" & standardized in 2005) and how this would affect OAR doses.
Introduction
Historically, breast radiation therapy (RT) treatment planning for node positive disease has involved creating a standard two-dimensional (2DRT) wedged plan on a single transverse contour taken through the center of the breast and then matched to a single anterior field to encompass the supraclavicular-axilla dosed to a depth of 3 cm [1] . Other disease sites have demonstrated an improvement in the therapeutic ratio using three dimensional conformal RT (3DCRT) or intensity modulated RT (IMRT), where the internal/external anatomical tissues/ organs are delineated and used in treatment planning. Clinical delivery for breast treatment using 2DRT is still common despite two clinical trials demonstrating a reduction in acute and late adverse effects when using 3DCRT/IMRT compared to 2DRT [2] [3] . More recently, contouring atlases for breast have been developed and the use of dose-volume goals has become a standard element of RT planning for patients on more recent Radiation Therapy Oncology (RTOG) and National Surgical Adjuvant Breast and Bowel Project (NSABP) breast clinical trials [4] [5] . However, the uses of 3DCRT/IMRT with target and organs at risk (OAR) dose-volume goals for NPBC patients undergoing regional nodal irradiation after lumpectomy/mastectomy have yet to be standardized nor has the use of such goals gained widespread use in standard practice. We have reviewed our own experience with 3DCRT for node positive breast cancer (NPBC) and have reported excellent local control, survival, and toxicity [6] [7] .
The purpose of this work is to retrospectively evaluate the plan quality of NPBC patients since our institution standardized the use of dose-volume goals (referred to as goals hereafter) in treatment planning of NPBC.
Methods

Patient Selection
A total of 262 NPBC patients were selected for this study and demographically consists of 81.1% (n = 212 cases) Caucasians, 39.4% (n = 40) African Americans, 7.6% (n = 8) Asians and 2 from Southeast Asia/India. Median patient age was 50 
Treatment Planning and Contouring
The target volumes were delineated on all cases and the dose prescribed accord- The supraclavicular and axilla nodal targets (levels 2 -3) were contoured in every case. The internal mammary lymph node chain (IMC) (defined by the intercostal artery and vein in the first 3 intercostal spaces) was contoured on 210 of 262 (80.2%) of cases; however the IMCs were not targeted in the remaining 52 of 262 (19.8%) cases. The contour of the lung was outlined using an auto-threshold segmentation algorithm. The heart was contoured by delineating both ventricles and the left atria. The heart was contoured mainly for left-sided NPBC patients; however the heart was contoured for some right-sided NPBC patients.
All cases over the study period were reconstructed using XiO treatment planning system [Elekta AB. (Stockholm, Sweden)] without modification to the original structure contours. Dose was calculations were performed using the fast superposition algorithm with inhomogeneity corrections turned on. The dose was prescribed to the ICRU reference point which was located in the lumpectomy or chestwall volume centroids. Each patient's dose-volume histogram (DVH) was used to calculate the acceptable goals listed in Table 1 for the WB, CW, regional lymph node structures, lung and heart. This dose-volume analysis was repeated for all patients in order to assess those cases meeting the acceptable institutional guidelines listed in Table 1 .
Treatment Planning Goals
In this study, we sought to compare dose-volume analyses from 3D treatment 
Analysis and Statistical Methods
We hypothesized that the use of institutional guidelines in treatment planning would lead to a statistically significant difference in target coverage in cases from 
Results
Meeting Target Goals
The (Table 3) . (Table 3) further demonstrate a trade-off between achieved lung and heart doses.
Discussion
In this study, we sought to investigate how the use of institutionally established dose-volume goals for 3DCRT planning of NPBC patients affected the dose delivered to targets and OAR. We demonstrated that using dose-volume goals does not lead to a statistically significant increase in doses to OAR (i.e. heart and lung), a concern that we had at the beginning of this analysis. Our clinical experience suggests that acceptable levels of normal tissue toxicity and good local control can be achieved with these 3DCRT goals in treating NPBC. For example, then underwent CT and delineation of the supraclavicular and axillary lymph nodes [9] . Evaluation of the CT defined nodal groups demonstrated a significant variation of the included nodes in the 2D defined treatment fields. Therefore, they concluded that nodal groups should be delineated on CT prior to field definition in order to achieve the desired target coverage. More recently, investigators have focused on using intensity-modulated RT (IMRT) techniques to achieve improved target coverage, avoidance of OAR, and as a means for cor- 
Conclusions
In conclusion, our study is the first to investigate the efficacy of using dosevolume goals in treatment planning for NPBC patients. Any retrospective analysis for breast RT of this type has limitations: 1) The variability introduced in the RT planning process wasn't discussed in the literature until [2007] [2008] [2009] (near the end of our study period), which makes it difficult to assess the impact of this effect on our results; 2) Contouring databases, like the RTOG breast atlas,
were not published until 2009, making it more difficult to assess differences in contouring in our analysis; and 3) The heart was not contoured for all WB/CW cases. Any institution should use dose-volume goals with caution given this variability in defining clinical and planning target volumes. One limitation of our retrospective study is that there was no consistent use of institutional dosevolume goals over the time period studied. Prior to 2005, plans were evaluated qualitatively slice by slice to visually ensure isodose lines covered targets and OAR were adequately spared. The DVHs were reviewed but not used to assess a plan as acceptable for treatment. A second limitation is that these goals were generated by our institutional experience well before there was much evidence in the literature regarding the optimal dose-volume goals for NPBC. In particular, recent breast cancer trails (e.g. NSABP B-51) have different heart goals for right and left sided WB/CW cases but our study used the same goals for both WB/CW cases [5] . However, the strengths of this study are that it is the first to our know-ledge to demonstrate in a large number of cases the feasibility of using dosevolume goals on DVHs to achieve an optimal 3DCRT treatment plan for NPBC.
In the future, clinical trials and prospective databases evaluating the treatment of node positive breast cancer will be ideally suited for prospective confirmation of these dose-volume goals.
